Omada Health Earnings Call Signals Profitable Scale

Omada Health, Inc. ((OMDA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Omada Health’s latest earnings call struck a confident tone, underscoring a business that is scaling fast while tightening its financial profile. Management emphasized robust top-line growth, expanding margins, and early profitability, arguing that recent headwinds are mostly timing and mix-related rather than structural. Investors heard a narrative of momentum, reinforced by raised guidance and a debt-free balance sheet.

Strong Revenue Growth and Raised Guidance

Omada reported Q1 2026 revenue of $78 million, up 42% year over year, showing that demand for its virtual chronic care model remains strong. The company lifted full-year revenue guidance to a range of $322 million to $330 million, implying roughly 25% growth at the midpoint and signaling confidence in continued commercial traction.

Membership Milestone and Enrollment Momentum

Total membership surpassed the seven-figure mark, ending the quarter at 1,025,000 members, a 51% jump from a year ago. Net adds reached 139,000 in Q1, up from 107,000 in the prior-year period, with management crediting Omada-led outreach and an improved enrollment experience that boosted conversion and multi-condition adoption.

Improved Profitability and Margins

Profitability trends moved in the right direction, with GAAP gross profit reaching $49 million and gross margin expanding to 62%, or 64% on a non-GAAP basis. The GAAP net loss narrowed to $3 million while adjusted EBITDA turned positive at $1 million, prompting management to raise full-year adjusted EBITDA guidance to $14 million to $20 million.

Stronger Operational Levers from AI and Product

Artificial intelligence is increasingly central to Omada’s operating model, embedded in care delivery, engineering, and back-office functions to boost efficiency. New AI-driven nutrition features such as Meal Map lifted weekly active meal tracking among new members by about 16%, illustrating how product innovation can drive engagement and, ultimately, outcomes.

Expanded Commercial Reach and PBM Relationships

The company deepened its commercial footprint by securing relationships with all three major pharmacy benefit managers, broadening access to employer and health plan clients. Inclusion in key PBM and pharmaceutical partner programs expands channels for GLP-1 prescribing and wraparound care, increasing Omada’s reach into commercially insured populations.

Clinical Evidence and GLP-1 Traction

Omada highlighted growing traction for its GLP-1 Care Track, which had supported more than 150,000 members by the end of last year. A new analysis showed participants lost 1.8 times more total weight and twice the body fat than controls over 12 weeks, with weight largely maintained a year after stopping therapy, supported by the company’s behavioral and clinical programs.

Healthy Balance Sheet and Debt-Free Position

The balance sheet remains a strategic asset, with Omada ending the quarter holding $212 million in cash and cash equivalents. Management noted that the company is now debt-free after repaying its term loan early, giving it ample runway to invest in growth, technology, and clinical capabilities without near-term financing pressure.

Near-Term Pressure on Blended Revenue per Member

One nuance for investors is that more members are now in their second year or later, which structurally lowers average revenue per member as pricing steps down over time. However, management stressed that mature cohorts carry higher gross margins, meaning per-member profitability improves even as headline revenue metrics face some mix-driven pressure.

Prescribing and New Channel Revenue Skewed to 2027

Omada’s new prescribing capabilities and several fresh commercial relationships are still in early ramp, limiting their expected revenue contribution in 2026. The company guided investors to view these channels as a more meaningful opportunity from 2027 onward, aligning with multi-year sales cycles and adoption curves in newly covered populations.

Incremental Shipping and Device Cost Headwind

Rising logistics costs created a modest headwind, as geopolitical tensions pushed up device-related shipping expenses. Management estimated the impact at around $1 million for the full year and is evaluating strategies such as pre-purchasing devices to stabilize costs and reduce exposure to future volatility.

Competitive and Multi-Vendor PBM Environment

While PBM partnerships broaden Omada’s access, they also come with competition since programs often feature multiple vendors rather than exclusive relationships. The company acknowledged it must continue investing in go-to-market execution and enablement to win share within these multi-vendor ecosystems and prove its differentiated value.

Sequential Growth Nuance and Disclosure Limits

Sequentially, growth looked modest due to a one-time $2 million revenue item in Q4 that did not repeat, but adjusting for that, Q1 revenue rose about 6%. Management also highlighted that some metrics, including the number of active GLP-1 users, were not disclosed at a quarterly level, reflecting the complexity and duration of sales cycles in newer segments.

Upgraded Outlook and Forward-Looking Commentary

Guidance moved higher across both revenue and profitability, with the new ranges effectively lifting the floor to the prior top end. Management tied its outlook to better retention, richer multi-condition mix, commercial momentum around PBM and GLP-1 offerings, and AI-enabled efficiency gains, while flagging only modest cost headwinds from shipping and emphasizing a path toward even higher long-term gross margins.

Omada’s earnings call painted the picture of a digital health company maturing into scale, pairing rapid member and revenue growth with improving unit economics and early profitability. While mix shifts, competitive PBM dynamics, and timing on new channels introduce some near-term noise, the overall trajectory remained positive, with raised guidance and a strong balance sheet supporting a constructive long-term view.